Nutraplus India Ltd
Nutraplus India is engaged in the Business of Drugs and Pharmaceuticals.
- Market Cap ₹ 7.16 Cr.
- Current Price ₹ 2.10
- High / Low ₹ /
- Stock P/E
- Book Value ₹ -1.67
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 5.00
Pros
Cons
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65.00 | 77.51 | 91.05 | 109.14 | 139.55 | 106.67 | 0.02 | 0.10 | -0.06 | 0.00 | 0.00 | 0.00 | |
| 61.79 | 65.37 | 92.78 | 99.83 | 126.89 | 142.44 | 0.38 | 3.75 | 0.07 | 0.06 | 0.05 | 0.50 | |
| Operating Profit | 3.21 | 12.14 | -1.73 | 9.31 | 12.66 | -35.77 | -0.36 | -3.65 | -0.13 | -0.06 | -0.05 | -0.50 |
| OPM % | 4.94% | 15.66% | -1.90% | 8.53% | 9.07% | -33.53% | -1,800.00% | -3,650.00% | ||||
| -2.94 | 1.48 | 0.99 | 0.12 | 1.58 | 0.08 | -23.36 | 0.62 | 0.00 | 0.00 | 0.00 | 0.16 | |
| Interest | 4.52 | 4.86 | 5.01 | 4.67 | 6.85 | 7.43 | 0.80 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
| Depreciation | 1.40 | 1.72 | 2.21 | 3.88 | 4.03 | 4.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -5.65 | 7.04 | -7.96 | 0.88 | 3.36 | -47.82 | -24.52 | -3.03 | -0.16 | -0.06 | -0.05 | -0.34 |
| Tax % | -28.14% | -12.64% | -21.36% | 84.09% | 34.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| -4.06 | 7.93 | -6.26 | 0.14 | 2.19 | -47.83 | -24.52 | -3.03 | -0.16 | -0.06 | -0.05 | -0.34 | |
| EPS in Rs | -1.66 | 2.85 | -1.84 | 0.04 | 0.64 | -14.03 | -7.19 | -0.89 | -0.05 | -0.02 | -0.01 | -0.10 |
| Dividend Payout % | 0.00% | 7.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | % |
| TTM: | -580% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -31% |
| 5 Years: | -4% |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11.16 | 12.67 | 17.05 | 17.05 | 17.05 | 17.05 | 17.05 | 17.05 | 17.05 | 17.05 | 17.05 | 17.05 |
| Reserves | 36.01 | 50.22 | 50.17 | 50.19 | 52.40 | 4.57 | -19.10 | -22.13 | -22.28 | -22.35 | -22.40 | -22.74 |
| 40.29 | 72.05 | 65.77 | 73.38 | 74.93 | 75.88 | 1.75 | 1.75 | 1.76 | 1.78 | 1.79 | 2.17 | |
| 26.60 | 30.66 | 37.27 | 31.21 | 25.32 | 39.37 | 34.99 | 12.28 | 8.72 | 8.77 | 8.73 | 8.52 | |
| Total Liabilities | 114.06 | 165.60 | 170.26 | 171.83 | 169.70 | 136.87 | 34.69 | 8.95 | 5.25 | 5.25 | 5.17 | 5.00 |
| 22.95 | 32.89 | 38.64 | 72.31 | 82.44 | 81.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 13.42 | 37.53 | 48.27 | 21.59 | 17.26 | 12.67 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 4.20 | 4.15 | 4.16 | 4.15 | 4.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| 73.49 | 91.03 | 79.19 | 73.78 | 65.85 | 42.86 | 34.42 | 8.80 | 5.10 | 5.10 | 5.02 | 4.85 | |
| Total Assets | 114.06 | 165.60 | 170.26 | 171.83 | 169.70 | 136.87 | 34.69 | 8.95 | 5.25 | 5.25 | 5.17 | 5.00 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.49 | -9.61 | 19.66 | 6.69 | 12.36 | 9.07 | -14.25 | -0.15 | 0.02 | -0.01 | 0.00 | -0.40 | |
| -5.10 | -34.42 | -18.59 | -10.70 | -9.74 | -2.69 | 93.77 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 31.53 | 35.54 | -1.91 | 4.00 | -2.66 | -7.57 | -80.25 | 0.00 | -0.03 | 0.02 | 0.00 | 0.39 | |
| Net Cash Flow | 9.94 | -8.48 | -0.84 | -0.01 | -0.03 | -1.18 | -0.73 | -0.03 | -0.01 | 0.01 | 0.00 | -0.01 |
| Free Cash Flow | -37.12 | -45.37 | 0.96 | -4.13 | 2.50 | 6.24 | 79.49 | -0.03 | 0.02 | -0.01 | 0.00 | -0.40 |
| CFO/OP | -514% | -72% | -1,139% | 80% | 103% | -26% | 3,958% | 4% | -15% | 17% | 0% | 80% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75.13 | 119.80 | 104.79 | 83.71 | 42.97 | 9.48 | 19,710.00 | 1,898.00 | -2,676.67 | |||
| Inventory Days | 134.40 | 181.03 | 113.18 | 110.73 | 124.02 | 89.78 | 363.97 | 0.00 | ||||
| Days Payable | 186.44 | 189.62 | 177.37 | 132.71 | 75.89 | 35.11 | 878.67 | |||||
| Cash Conversion Cycle | 23.09 | 111.21 | 40.60 | 61.73 | 91.10 | 64.15 | 19,710.00 | 1,383.31 | -2,676.67 | |||
| Working Capital Days | 60.53 | 117.30 | 20.61 | 28.43 | 1.99 | -160.65 | 447,855.00 | 0.00 | -22,386.67 | |||
| ROCE % | 2.89% | 9.65% | -2.85% | 4.06% | 8.78% | -33.35% | -0.56% |
Insights
In beta| Sep 2016 | Mar 2020 | Jun 2025 | |
|---|---|---|---|
| Number of Manufacturing Units Number |
|
||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Secretarial compliance report for FY2026 notes delisting suspension, Rs36,76,880 fines paid, and SAT re-listing order dated 19 Jan 2026.
-
Intimation That Nutraplus India Limited Has Decided To Set Up Commercial Bio Gas (CBG) Plant.
29 May - On May 29, 2026, Nutraplus India plans to set up a Commercial Bio Gas plant.
-
Audited Standalone Financial Statement With Independent Audit Report.
25 May - FY26 audited standalone results show Rs34.01 lakh loss, negative net worth Rs569.02 lakh, and qualified opinion.
-
Board Meeting Outcome for Outcome Of Board Meeting
25 May - Board approved FY26 audited standalone results; loss Rs34.01 lakh, negative net worth Rs569.02 lakh, qualified audit opinion.
-
Board Meeting Intimation for Intimation Of Board Meeting For 25/05/2026
19 May - Board meeting on 25 May 2026 to approve audited standalone results for quarter and year ended 31 March 2026.
Annual reports
Concalls
-
Sep 2016TranscriptAI SummaryPPT